Valuation: Gilead Sciences, Inc.

Market Cap 210B 187B 172B 157B 297B 19,685B 304B 2,063B 822B 10,539B 788B 771B 33,193B P/E 2026 *
-39.7x
P/E 2027 * 20.4x
Enterprise Value 231B 206B 190B 172B 326B 21,658B 335B 2,270B 905B 11,595B 867B 849B 36,519B EV / Sales 2026 *
7.37x
EV / Sales 2027 * 6.6x
Free-Float
99.89%
Yield 2026 *
1.95%
Yield 2027 * 1.99%
1 day+1.46%
1 week-0.59%
Current month-0.80%
1 month+12.01%
3 months+27.11%
6 months+28.93%
Current year+37.95%
1 week 164
Extreme 164
176.58
1 month 147.26
Extreme 147.26
176.58
Current year 116.88
Extreme 116.88
176.58
1 year 116.88
Extreme 116.88
176.58
3 years 62.07
Extreme 62.07
176.58
5 years 57.16
Extreme 57.165
176.58
10 years 56.56
Extreme 56.56
176.58
Manager TitleAgeSince
Chief Executive Officer 61 01/03/2019
Director of Finance/CFO 56 01/11/2019
Compliance Officer - 18/12/2025
Director TitleAgeSince
Director/Board Member 58 19/08/2016
Director/Board Member 73 01/01/2018
Director/Board Member 72 09/05/2018
Date Insider Type Main position Quantity % Market Cap. Importance
2/11/26 Sell

Chief Executive Officer

-15,000 0.0012%
15/10/26 Sell

Executive/Senior Manager

-3,000 0.0002%
15/10/26 Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+1.46%-0.59%+42.48%+125.82% 207B
+4.28%+0.07%+52.75%+138.78% 1,206B
+2.13%+4.27%+51.21%+91.36% 665B
+0.68%+1.54%+33.83%+112.47% 515B
+2.77%+0.98%+49.44%+68.46% 381B
+1.38%+0.27%+72.42%+45.30% 362B
+0.29%+1.48%+30.84%+58.32% 307B
+0.98%+1.49%+9.04%+34.78% 289B
+1.04%-0.05%+45.29%+76.18% 249B
+1.24%+0.96%-6.32%-60.78% 177B
Average +1.66%+0.45%+38.10%+69.07% 436B
Weighted average by Cap. +2.25%+0.67%+43.87%+89.67%

Financials

2026 *2027 *
Net sales 31.36B 27.99B 25.76B 23.38B 44.31B 2,940B 45.41B 308B 123B 1,574B 118B 115B 4,957B 33.58B 29.97B 27.58B 25.03B 47.43B 3,147B 48.61B 330B 131B 1,685B 126B 123B 5,307B
Net income -5.29B -4.72B -4.35B -3.94B -7.48B -496B -7.66B -51.99B -20.72B -266B -19.86B -19.44B -836B 10.7B 9.55B 8.79B 7.97B 15.11B 1,003B 15.49B 105B 41.89B 537B 40.15B 39.29B 1,691B
Net Debt 21.05B 18.79B 17.29B 15.69B 29.73B 1,973B 30.47B 207B 82.42B 1,056B 79B 77.31B 3,326B 11.61B 10.36B 9.54B 8.66B 16.4B 1,088B 16.81B 114B 45.47B 583B 43.58B 42.65B 1,835B
Projected Income Statement - Annual - Gilead Sciences, Inc.
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
09/11/26 USD 169.32 +1.46% 4,470,450
06/11/26 USD 166.89 -0.41% 5,817,788
05/11/26 USD 167.57 -3.96% 11,355,969
04/11/26 USD 174.48 +4.19% 9,636,516
03/11/26 USD 167.47 -1.68% 6,606,702
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Gilead Sciences, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
169.32USD
Average target price
174.77USD
Spread / Average Target
+3.22%
  1. Stock Market
  2. Stocks
  3. GILD Stock